Research
Hormonal
In patients with advanced chronic liver disease (ACLD), achieving >10% body weight loss through therapeutic lifestyle interventions significantly reduces portal hypertension and improves survival, although this magnitude of weight loss is difficult to sustain long-term.
For ACLD patients, aiming for >10% weight loss via diet and exercise can significantly lower portal pressure and improve survival. However, this is hard to maintain; consider medical weight loss aids if lifestyle changes alone fail to sustain the loss.
GoodQualifiesMEDIUM confidence
a significantly greater decrease in HVPG was observed in patients achieving >10% weight loss, and no clinical decompensation occurred... more than 20% of patients returned to baseline weight within 3 years, including 60% of them within 1 year.
Why this rating
Based on small retrospective and uncontrolled studies, but consistent with larger MASLD data.
Source
Management of obesity in advanced chronic liver disease
Cyrielle Caussy et al. · JHEP Reports · 2026
DOI 10.1016/j.jhepr.2026.101749
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Novel anti-obesity medications (AOMs), specifically GLP-1 receptor agonists like semaglutide (2.4 mg weekly), achieve >10% body weight loss and lead to MASH resolution and fibrosis regression in patients with fibrotic MASH, offering a viable alternative to lifestyle changes alone.Strong
- Bariatric surgery is an effective and durable weight-loss intervention that reduces major adverse liver outcomes (MALO) and cardiovascular events in patients with MASH, though data in advanced cirrhosis is limited.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →